Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Review uri icon

Overview

abstract

  • Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.

publication date

  • September 1, 2006

Research

keywords

  • Carrier Proteins
  • Receptors, Fc
  • Thrombocytopenia

Identity

Scopus Document Identifier

  • 33748674848

PubMed ID

  • 17002262

Additional Document Info

volume

  • 7

issue

  • 9